CoChat

An Indistinct Balance: The Safety and Efficacy of Parenteral Iron Therapy

BESARAB, ANATOLE, FRINAK, STANLEY, YEE, JERRY · 1999 · Journal of the American Society of Nephrology
Cited by 91

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

The National Kidney Foundation Dialysis Quality Initiatives (NKF-DOQI) Anemia Work Group developed clinical practice guidelines (1) that aimed to achieve a target hemoglobin level of 11 to 12 g/dl at the lowest cost by optimizing the erythron response to recombinant human erythropoietin (epoetin). Despite the use of epoetin to manage the anemia of chronic renal failure (CRF) (2,3,4,5,6), many patients remain at hematocrits below currently recommended levels. Persistence of suboptimal hematocrit levels despite administration of seemingly adequate doses of epoetin signifies an inadequate response to the agent. The most common cause for such erythropoietin resistance is an inadequate supply of iron to the bone marrow to sustain enhanced erythropoiesis (7,8,9,10,11,12,13). The NKF-DOQI Anemia Work Group guidelines support the implementation of a proactive intravenous iron maintenance regimen. Given that gastrointestinal iron absorption is less than ongoing iron losses in the majority of hemodialysis (HD) patients, functional iron deficiency is likely to develop in most patients leading to an iron-limited erythropoiesis. We define functional iron deficiency as a pathophysiologic state in which the bone marrow's erythropoietic capacity to respond to epoetin is limited by iron release from storage depots. The result of such deficiency is utilization of higher and more costly doses of epoetin to overcome what is errantly perceived as relative resistance to epoetin. Parenteral iron is the treatment of choice in HD patients with either absolute or functional iron deficiency since oral iron therapy is nearly always ineffective in the dialysis population. In fact, the NKF-DOQI guidelines advocate aggressive detection and management of functional iron deficiency. An initial and careful scrutiny of the iron status of the dialysis patient is succeeded by the optimized delivery of parenteral iron and epoetin to achieve the desired level of erythropoiesis. Excessive fear of the potential risks associated with iron therapy may lead the practitioner to adopt a skewed view of the role of iron and epoetin in the management of the anemia of CRF. In this venue, iron has a passive role that justifies maintenance of iron stores and transferrin saturation (TSAT) at low levels since epoetin resistance can be overcome by increasing epoetin dose. In this scenario, the means to achieve target hemoglobin levels of 11 to 12.5 g/dl become subsidiary to the goal because the benefits of anemia correction (i.e., decreased mortality, decreased hospitalization, and improved quality of life) are gained only after attaining target hemoglobin levels. This rationalization underestimates the role of appropriate iron prescription, dismissing its cost effectiveness in the global management of the dialysis patient. Furthermore, hemoglobin levels are generally more stable over time during judicious application of iron, avoiding the fluctuating hemoglobin levels that are frequently present during epoetin-centric anemia management. Reducing the epoetin dose in patients may attenuate several potentially untoward effects of epoetin. Epoetin may promote hypertension by inducing vascular constriction through enhanced endothelin-1 production and by reducing the vasodilatory response of resistance vessels by decreasing endothelial nitric oxide production (14). Furthermore, epoetin-mediated platelet-derived growth factor release by vascular smooth muscle cells (15) may promote atherogenesis and myointimal hyperplasia, particularly in vascular access grafts of HD patients. A more balanced view of risks and benefits associated with epoetin and iron in anemia management is depicted in Figure 1.Figure 1.: Relative benefits and risks of epoetin (EPO) and parenteral iron (Fe) use. Increasing hemoglobin to >10 g/dl by using EPO can reduce morbidity, mortality, and hospitalization, but may induce hypertensive effects or effects on vascular smooth muscle cells (VSMC) that may produce undesired effects on vascular access function. Similarly, parenteral iron may be associated with unwanted effects, but prevention of iron deficiency is cost-effective and may promote stability of hemoglobin, prevent multiple dosing changes in EPO, and improve blood flow through capillaries by improving the rheologic properties of red blood cells.What is the relative safety of maintaining a higher ferritin level in HD patients through repeated administration of intravenous iron? Moreover, what levels of serum ferritin warrant concern for iron overload? Parameters that most frequently stimulate treatment by iron are a set of suboptimal iron indices, TSAT, and serum ferritin. Despite their wide application, these parameters frequently fail to detect functional iron deficiency (16,17,18). Several studies have explored the issue of whether increased risks exist for those end-stage renal disease (ESRD) patients whose ferritin levels consistently exceed 500 ng/ml (19) and for those who receive iron

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.v1092029

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 91

Metadata

Authors
BESARAB, A., FRINAK, S., & YEE, J.
Venue
Journal of the American Society of Nephrology
Published
1999-09
Volume
10
Issue
9
Pages
2029-2043
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2142471162
Cited by
91
References
6
FWCI
1.83
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An Indistinct Balance: The Safety and Efficacy of Parenteral Iron Therapy. https://app.cochat.ai/papers/10.1681/asn.v1092029
The paper
BESARAB, A., FRINAK, S., & YEE, J. (1999). An Indistinct Balance: The Safety and Efficacy of Parenteral Iron Therapy. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.v1092029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.